Edition:
United Kingdom

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

38.40USD
5:03pm GMT
Change (% chg)

$0.38 (+1.00%)
Prev Close
$38.02
Open
$38.11
Day's High
$38.92
Day's Low
$37.37
Volume
146,714
Avg. Vol
316,944
52-wk High
$49.15
52-wk Low
$24.68

Latest Key Developments (Source: Significant Developments)

Radius Health Expects CHMP To Issue Opinion Regarding Marketing Authorization Application Of Abaloparatide-Sc during H1 2018
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Radius Health Inc ::RADIUS HEALTH ANNOUNCES THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) WILL ISSUE A THIRD DAY-180 LIST OF OUTSTANDING ISSUES IN ITS REGULATORY REVIEW OF ABALOPARATIDE-SC, A BONE BUILDING AGENT FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURE.RADIUS HEALTH-EXPECTS COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE TO ISSUE AN OPINION REGARDING MARKETING AUTHORISATION APPLICATION DURING H1 2018.  Full Article

Radius Health reports Q3 loss per share $1.31
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Radius Health Inc :Radius Health Inc reports third quarter 2017 financial and operating results and provides business update.Q3 loss per share $1.31.Q3 earnings per share view $-1.26 -- Thomson Reuters I/B/E/S.Radius Health Inc - ‍expects to submit a labeling supplement to FDA in connection with activextend results by end of 2017​.Radius health inc - ‍expects to reduce size of board from 10 to 9 members​.Radius Health Inc - believe have sufficient capital to fund development plans, U.S. Commercial and other operational activities for not less than 12 months​.  Full Article

Radius Health receives FDA fast track designation for elacestrant
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Radius Health Inc :Radius health receives fda fast track designation for elacestrant (rad1901).Radius health - ‍plans to initiate phase 2 clinical study of elacestrant as a third-line therapy for women with er+ and her2- breast cancer early in 2018​.Radius health inc - ‍expect to enroll first patient in phase 2 study in early 2018​.  Full Article

Radius Health Q2 loss per share $1.01
Thursday, 4 Aug 2016 

Radius Health Inc : Q2 loss per share $1.01 .Q2 earnings per share view $-0.95 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Radius Health Expects CHMP To Issue Opinion Regarding Marketing Authorization Application Of Abaloparatide-Sc during H1 2018

* RADIUS HEALTH ANNOUNCES THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) WILL ISSUE A THIRD DAY-180 LIST OF OUTSTANDING ISSUES IN ITS REGULATORY REVIEW OF ABALOPARATIDE-SC, A BONE BUILDING AGENT FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURE